The Swiss National Bank has pared back its investment in dental-equipment maker DENTSPLY SIRONA, selling 13,600 shares in the first quarter. The move cuts the central bank’s position by 3.4 percent to 385,100 shares—about 0.19 percent of the company, according to a newly filed SEC disclosure.
Subscribe
Stock Market
Swiss National Bank Lowers Stock Holdings in DENTSPLY SIRONA Inc. $XRAY
Key Takeaways:
- Swiss National Bank reduced its DENTSPLY SIRONA holdings by 3.4 percent.
- The central bank sold 13,600 shares during the first quarter.
- Its remaining stake totals 385,100 shares.
- That position represents roughly 0.19 percent of the company.
- The changes were revealed in an SEC filing dated Aug. 19 2025.
The News
A newly released filing with the U.S. Securities and Exchange Commission shows that the Swiss National Bank has quietly trimmed its stake in DENTSPLY SIRONA Inc. (NASDAQ: XRAY). The first-quarter disclosure reports the sale of 13,600 shares, a 3.4 percent reduction that leaves the central bank with 385,100 shares of the medical-instrument supplier.
The Numbers
| Metric | Before Sale* | After Sale | Change | |—|—|—|—| | Shares held | 398,700 | 385,100 | –13,600 | | Percentage of company | ~0.20 % | ~0.19 % | –0.01 pp |
*Calculated from figures in the SEC filing.
Why It Matters
Even modest portfolio shifts by large institutional investors tend to draw notice on Wall Street. Central banks, in particular, are watched for clues about broader market sentiment. While a 3.4 percent trim is small in absolute terms, the filing provides a snapshot of how the Swiss National Bank fine-tunes its equity exposure.
Inside the Filing
The document, dated Aug. 19 2025, covers activity in the first quarter of the year. Under U.S. regulations, institutional investors with sizeable holdings must disclose their positions periodically, offering the public a window into their trading activity.
A Modest Slice
Following the sale, the Swiss National Bank’s 385,100-share position amounts to roughly 0.19 percent of DENTSPLY SIRONA’s outstanding stock—still a meaningful, if minor, slice of the company. The filing did not provide commentary on the bank’s rationale, and no further transactions were detailed.
Looking Ahead
For now, the adjustment stands as a routine portfolio move rather than a sweeping strategic shift. But as investors parse future filings, any additional changes—large or small—will continue to inform the market’s view of institutional appetite for DENTSPLY SIRONA and the broader medical-devices sector.
